Johnson & Johnson’s much-hyped Icotyde pill shows another biologic-like efficacy in inflammatory diseases, with a phase 3 win ...

Eli Lilly could soon see two label expansions for Foundayo, it’s oral GLP-1, in swift succession: In September, the drugmaker ...

Sticking by the strong relationship Moderna has fostered with the United Kingdom, the mRNA specialist is relocating its home base in the country to a different part of the capital.  | Sticking by the ...

After playing a key role in sparking a new era in cancer treatment through its work in antibody drug conjugates (ADCs), Daiichi Sankyo is pursuing an even bigger ambition: to shape what comes next in ...

Against a backdrop of repeated industry challenges in court, the Centers for Medicare and Medicaid Services (CMS) is locking ...

Amid surging sales of Rezdiffra, Madrigal Pharmaceuticals is facing a whistleblower lawsuit alleging that senior leadership ...

AstraZeneca may not need a major acquisition to sustain growth beyond 2030—but the British pharma is reportedly not stopping ...

Bayer’s pharmaceutical business may finally be entering a long-awaited growth cycle, but CEO Bill Anderson still can’t quite ...

ViiV Healthcare has tapped a new mind for its “PrEP Wisdom” campaign, with Tony Award-winning actor and fashion icon Jeremy ...

Karyopharm Therapeutics filed for Chapter 11 bankruptcy as part of a plan to merge with Irish hematology biotech, Ayrmid. Massachusetts-based Karyopharm’s financial woes came to a head in August, when ...

The team at Evercore ISI, for its part, claimed Rasonque’s debut was nothing short of “eye-popping.” The shop is now looking at a potential $500 million in Rasonque sales for the year’s final quarter, ...

Knudsen’s departure will mark the end of a 27-year run at Novo, with Doustdar telling analysts Wednesday that the outgoing ...